Scholarlink

<p>Reirradiation has re-emerged as a viable salvage modality for recurrent central nervous system (CNS) tumors in the modern era of precision radiotherapy. Advances in image guidance, biological understanding of normal-tissue repair, and integration of targeted systemic agents have expanded its therapeutic window. The 2025 ISRS meta-analysis (62 studies; n = 2640) established a median overall survival (OS) of ~ 10.2&#xa0;months after re-irradiation (re-RT) of recurrent HGG, confirming that focal single-fraction SRS (16&#xa0;Gy × 1) or hypofractionated SRS (25&#xa0;Gy/5 fx) achieves optimal tumor control with acceptable neurologic toxicity (7% vs 4%). EQD₂ &gt; 120–130&#xa0;Gy markedly increases radionecrosis risk (p = 0.003). Integration of DNA-damage-repair (DDR) inhibitors, VEGF blockade, and tumor-treating fields (TTFields) is under active investigation. Re-RT in ependymoma, meningioma, and spinal tumors is also gaining renewed interest with proton and MR-guided adaptive techniques.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Precision reirradiation in recurrent CNS tumors integrating biology techniques and multimodal care

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月27日

查看全文
  • N. Volkan Demircan

摘要

Reirradiation has re-emerged as a viable salvage modality for recurrent central nervous system (CNS) tumors in the modern era of precision radiotherapy. Advances in image guidance, biological understanding of normal-tissue repair, and integration of targeted systemic agents have expanded its therapeutic window. The 2025 ISRS meta-analysis (62 studies; n = 2640) established a median overall survival (OS) of ~ 10.2 months after re-irradiation (re-RT) of recurrent HGG, confirming that focal single-fraction SRS (16 Gy × 1) or hypofractionated SRS (25 Gy/5 fx) achieves optimal tumor control with acceptable neurologic toxicity (7% vs 4%). EQD₂ > 120–130 Gy markedly increases radionecrosis risk (p = 0.003). Integration of DNA-damage-repair (DDR) inhibitors, VEGF blockade, and tumor-treating fields (TTFields) is under active investigation. Re-RT in ependymoma, meningioma, and spinal tumors is also gaining renewed interest with proton and MR-guided adaptive techniques.